and pediatric GBM cells. Bio-informatics analysis were used to refine this list and the top seven downstream mechanism of the strongest and most consistent candidate was investigated by siRNAs, 1 0 4
3'UTR luciferase assays and Western Blotting. Results: Our screen identified ~100 significantly 1 0 5 cytotoxic microRNAs with 70% concordance between cell lines. MicroRNA-1300 (miR-1300) was 1 0 6 the most potent and robust candidate. We observed a striking binucleated phenotype in miR-1300 1 0 7
expressing cells and characterized the mechanism of action as cytokinesis failure followed by novel regulator of endomitosis with translatable potential for therapeutic application. The datatasets 1 1 5
will be a resource for the neuro-oncology community. MicroRNAs are small 22-24nt single-stranded non-coding RNAs that function by reducing the 1 3 9
translation of target mRNAs. In glioblastoma (GBM), they have been shown to play roles in 1 4 0 proliferation, invasion and stemness, suggesting that microRNAs and their downstream pathways may 1 4 1 represent potent therapeutic targets (1) (2) (3) (4) (5) (6) . There is an increasing number of microRNA mimics and 1 4 2 inhibitors in pre-clinical and early clinical development in cancer, including one for patients with 1 4 3 solid tumors using a mimic of microRNA-34 (MRX34, Mirna Therapeutics Inc., NCT01829971) (7-1 4 4 10). Recent pre-clinical studies showed efficacy of a microRNA expressing therapeutic vector in 1 4 5 GBM (11). MicroRNA-10b expression has been measured in a clinical trial (NCT01849952) to assess 1 4 6 its use as a prognostic and diagnostic biomarker. An inhibitor of miR-10b is also currently at the 1 4 7 preclinical development stage (Regulus Therapeutics Inc. and (12)). Current approaches for microRNA studies in GBM mainly involve endogenous microRNA expression 1 4 9
profiles coupled with bioinformatic analysis and target identification to link the landscape of 1 5 0 microRNA expression to GBM biology and disease outcome (13) (14) (15) . Other functional studies have 1 5 1 focused on small numbers of microRNAs and very few large scale functional studies have been 1 5 2 performed in GBM (16).
5 3
To access the landscape of potential cytotoxic microRNAs in GBM we decided on a global approach 1 5 4
by performing a large-scale functional screen. We used a microRNA mimic oligonucleotide library 1 5 5 combined with a high-throughput imaging platform to identify microRNAs that significantly impaired 1 3
( Figure 1C ) suggested that cell cycle arrest took place after telophase and is representative of Next, we sought to confirm that this phenotype was also observed in patient-derived glioma stem-like 3 0 8 cells (GSCs) as a more representative in vitro model. We used two previously characterized GSCs, 3 0 9
GBM1 and GBM4 (23, 24) and performed new time courses for the flow cytometry assays at 72, 96
and 120 hours to reflect the slower division rate of the patient-derived cells, and we repeated the imaging experiments with binucleation scoring at 96 hours. Transfection of GBM1 with mimic miR- G0/G1 and S phase (Figure 2A ). This G2/M arrest led to an overall reduction in live cells of 3 1 6 approximately 40%, 45% and 80% at 72, 96 and 120 hours and a significant increase (p<0.01 and 3 1 7
p<0.05 in GBM1 and GBM4 respectively) in apoptotic cells at 120 hours ( Figure 2B ). Similar results 3 1 8
were observed in GBM4 GSCs with miR-1300 causing a 65% reduction in cells in S-phase at 72 3 1 9
hours which was maintained at 96 hours. At 96 hours there was an increase in cells on G2/M phase by 3 2 0 4-fold for GBM1 and by 2-fold for GBM4 ( Figure 2A ). At 96 hours, miR-1300 transfection resulted 3 2 1
in an approximately 40% reduction in live cells and an increase of around 20% in early-mid apoptotic 3 2 2 GBM1 cells. By 120 hours there was an approximately 75% decrease in live cells and a 1.5-fold 3 2 3 increase in early-mid apoptotic for both GBM1 and GBM4 and 2.5 and 1.5-fold increase in mid-late miR-1300 on the number of bi-and multi-nucleated cells. As with the established cell lines, miR-1300
caused a decrease in mono-nucleated cells of approximately 90% in both GBM1 and GBM4 and a 1 4
Taken together, this initial characterization showed that ectopic expression of miR-1300 consistently 3 3 0 led to failure of cytokinesis, measured by cell cycle arrest in G2/M phase and manifested by a striking 3 3 1 binucleated phenotype followed by the onset of apoptosis as documented by caspase-3 cleavage 3 3 2 (Suppl. Figure 2B /C) and expression of AnnexinV/PI ( Figures 1B and 2B ). This was confirmed both Since there are no validated target genes for miR-1300, we used the list of predicted targets extracted 3 3 7
from the online database TargetScan v5.2 (34). This contains 3327 target genes predicted to be is poorly conserved across species). We then loaded this list in the Metacore gene analysis software 3 4 0 (Thomson Reuters) and cross-referenced it using AmiGO (37) for "cytokinesis" as a Gene Ontology term. This allowed us to identify which of the miR-1300 target genes had the highest potential prediction score, and the literature, we chose the guanine nucleotide exchange factor (GEF) ECT2 3 4 5
(Epithelial Cell Transforming 2) as our target of interest for initial validation. Interestingly, ECT2 has 3 4 6 been previously described as an oncogene and has been shown to contribute to the invasive behavior 3 4 7 of GBM cells (38) (39) (40) (41) (42) . ECT2 plays a crucial role in cytokinesis through activation of the small 3 4 8
GTPase RhoA, a key protein in the formation of the mitotic cleavage furrow during cytokinesis (17, 3 4 9 18). It has also been shown that treatment of cells with RhoA inhibitors caused a binucleated 3 5 0 phenotype similar to that observed in the GBM cell lines following transfection with miR-1300 (43). Further, ECT2 depletion has been shown to lead to cytokinesis failure by impairment of cleavage- an inverse relation between ECT2 mRNA and miR-1300 expression (Suppl. Figure 4A ). This is 3 5 5 consistent with the frequency of multinuclear cells observed during cell culture (Suppl. Figure 4B ). Together, this data implicates ECT2 as a miR-1300 target that may play a role in mediating its effects 3 5 7 on glioblastoma cells. In order to validate ECT2 as a direct target of miR-1300, we first transfected U251 and KNS42 cells Figure 5B) ). Figures 50% in U251 and KNS42 cells respectively ( Figure 3C and Suppl. Figure 5A ); siRNA mediated 3 6 7
knock-down of ECT2 caused an increase in bi-and multi-nucleated cells of approximately 40% and 3 6 8 15%, respectively. A similar trend was observed in KNS42 cells ( Figure 3A and 3B ). In addition,
Western blotting experiments confirmed that transfection with miR-1300 induces a decrease in the Figure 5A ). Experiments in the patient-derived GSCs produced the same result (Suppl.
3 7 2 Figure 6 ). We did observe structural differences in actin and tubulin between miR-1300 expressing 3 7 3
and ECT2 knock-down cells by immunofluorescence ( Figure 3B ). This indicates that other miR1300 3 7 4 target genes, likely from the list of 21 targets we previously identified (Suppl. Having shown that the miR-1300 phenotype is consistent amongst a range of established and patient-3 7 7
derived GBM lines and that ECT2 is a promising target of miR-1300 across all cell lines tested, we 3 7 8 went on to confirm direct targeting using 3'UTR reporter assays in the established KNS42 cell line and one patient-derived GSC culture (GBM4). Cells were transfected with a luciferase reporter Methods). Co-transfection of either KNS42 or GBM4 with miR-1300 and 3'ECT2 caused a 1 6 respectively). In cells transfected with 3'ECT2-mt the effect of miR-1300 on the reporter signal was 3 8 5
abolished thus showing that the ECT2 3'UTR is a direct target of miR-1300 ( Figure 4A and B, 3 8 6 respectively).
8 7
In order to further validate the involvement of ECT2 in the pathway downstream of miR-1300, we 3 8 8
performed rescue experiments as follows; 36 hours following transfection with miR-1300 in KNS42 3 8 9 cells (~60h in GBM1 cells), cells were transfected again with an expression vector for ECT2 (lacking 3 9 0 the 3'UTR region) in an attempt to rescue cells from cytokinesis failure. We showed that re-3 9 1 expression of ECT2 caused a 50% reduction in the number of binucleated cells in both KNS42 and Endogenous levels of ECT2 mRNA and protein are known to be decreased during megakaryocytic 3 9 7 differentiation at the endomitotic stage when multinucleation occurs (19). This suggests a likely approximately 6-fold at 72h and a concomitant decrease in ECT2 protein levels following exposure to 4 0 6 5μM SU6656 ( Figure 5A and suppl. Figure 7) . Moreover, we confirmed the increase of polyploid 4 0 7 megakaryocytic cells by nearly 2-fold at 24h, and 1.5-fold both at 48h and 72h respectively, using 4 0 8
high-content immunofluorescence imaging ( Figure 5B ). In order to establish whether the phenotype caused by miR-1300 was specific to glioma cells, we 4 1 2 assessed the effect of its ectopic expression on fully differentiated GSCs, compared to their stem-like, 4 1 3 proliferative (isogenic) counterparts. Differentiation of GBM1 and GBM4 cells was achieved by 5 4 1 4 days exposure to BMP4 as previously described (22-24, 46, 47) .
In GBM1 cells, transfection with miR-1300 caused a 4-fold increase in the proportion of cells in 4 1 6 G2/M phase, which was significantly reduced by 2.3-fold in the BMP4 differentiated counterparts 4 1 7
( Figure 6A ). In addition, miR-1300 caused a 1.5-fold reduction in live cell numbers, a 3.8-fold 4 1 8 increase in early apoptotic cells and a 14-fold increase in apoptotic cells, whereas there was no 4 1 9 significant change in their differentiated counterparts ( Figure 6B ). We also observed a reduction by which was reduced to a 0.2-fold after BMP4 treatment ( Figure 6A ). MiR-1300 caused a 50% differences in comparison with the scrambled control transfected cells ( Figure 6B ). In addition, BMP4 4 2 7 treated GBM4 cells did not show an increased number of binucleated cells compared to control cells, 4 2 8
as opposed to their non-differentiated counterparts ( Figure 7B ). Taken together these data suggest that Our high-throughput screen defined the landscape of microRNAs with significant cytotoxic effects in 4 3 5
adult and pediatric GBM cell lines. We have shown that ectopic expression of miR-1300, the most potent candidate highlighted by the 4 3 7
screen, leads to cytokinesis failure followed by apoptosis in both established and in patient-derived repopulating cells it could also significantly impair recurrence.
5
Ongoing work is aimed at validating the mechanism of action of miR-1300 in more detail as well as 4 4 6
addressing delivery of microRNAs for brain tumor treatment and its potential use in combination with 4 4 7 conventional treatments. training, advice and analysis support for all confocal microscopy and flow-cytometry based assays. References: 
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